Theranos: Blood-Testing Startup Built on Technology That Never Worked
What happened
Theranos claimed its Edison device could run hundreds of medical tests from a single finger-prick of blood. In reality, most tests were run on conventional third-party lab equipment. When WSJ reporter John Carreyrou exposed the fraud in 2015, Theranos was valued at $9 billion. Founder Elizabeth Holmes was convicted of fraud in 2022.[1]
What went wrong
Theranos's leadership continued to demonstrate non-functional technology to investors and patients while concealing that results were produced by conventional machines. The board lacked medical expertise and did not require independent scientific validation. Regulatory oversight by CMS came years too late.[1]
Lesson learned
Deep-tech claims require independent scientific validation before deployment in medical contexts. A board that cannot evaluate technical claims is not qualified to provide oversight. Patients making medical decisions based on fraudulent test results is one of the most serious consumer harms possible.
Sources
- [1] Wall Street Journal Theranos: Blood-Testing Startup Built on Technology That Never Worked